Selected Laboratory Abnormalities in Patients With Kaposi’s Sarcoma–Associated Herpesvirus Inflammatory Cytokine Syndrome (n = 6) and All Other Group 4 Patients (n = 153)
| Characteristic . | Possible KICS Subjects (n = 6) . | Remainder of Patients Without Microbiologically Proven Coinfection (n = 153) . | P Value . | ||
|---|---|---|---|---|---|
| . | Abnormala, No. (%) . | Median (Range) . | Abnormala, No. (%) . | Median (Range) . | . |
| KSHV-VL, copies/106 cells | 6 (100) | 699.6 (160.7–2 165 641) | 2 (1) | 1.00 (1.00–104 664.39) | < .0001 |
| K8.1 OD | 6 (100) | 2.1 (1.3–2.3) | 46 (30) | 0.48 (0.10–2.57) | .001 |
| ORF73 OD | 4 (67) | 3.3 (0.32–7.4) | 33 (22) | 0.24 (0.03–8.14) | .003 |
| IL-6, pg/mL | 5 (83) | 11.5 (1.6–3 307.4) | 97 (63) | 12.5 (1.6–1 045.4) | .978 |
| CRP, mg/L | 6 (100) | 71.4 (11.1–304) | 131 (85) | 94.0 (0.38–564.9) | .767 |
| Hemoglobin, g/dL | 5 (83) | 8.1 (6.9–14.9) | 130 (85) | 10 (4.9–17.4) | .231 |
| White cell count, ×103/µL | 1 (17) | 7.6 (3.5–21.6) | 25 (16.3) | 6.8 (1.0–43.2) | .783 |
| Platelet count, ×103/µL | 4 (67) | 185 (89.0–305) | 29 (19) | 280 (23.0–789) | .050 |
| Albumin, g/L | 5 (83) | 24.0 (16.0–39.0) | 118 (77) | 28.0 (12.0–43.0) | .489 |
| Sodium, mEq/L | 5 (83) | 132 (125–138) | 119 (78) | 131 (113–150) | .692 |
| Characteristic . | Possible KICS Subjects (n = 6) . | Remainder of Patients Without Microbiologically Proven Coinfection (n = 153) . | P Value . | ||
|---|---|---|---|---|---|
| . | Abnormala, No. (%) . | Median (Range) . | Abnormala, No. (%) . | Median (Range) . | . |
| KSHV-VL, copies/106 cells | 6 (100) | 699.6 (160.7–2 165 641) | 2 (1) | 1.00 (1.00–104 664.39) | < .0001 |
| K8.1 OD | 6 (100) | 2.1 (1.3–2.3) | 46 (30) | 0.48 (0.10–2.57) | .001 |
| ORF73 OD | 4 (67) | 3.3 (0.32–7.4) | 33 (22) | 0.24 (0.03–8.14) | .003 |
| IL-6, pg/mL | 5 (83) | 11.5 (1.6–3 307.4) | 97 (63) | 12.5 (1.6–1 045.4) | .978 |
| CRP, mg/L | 6 (100) | 71.4 (11.1–304) | 131 (85) | 94.0 (0.38–564.9) | .767 |
| Hemoglobin, g/dL | 5 (83) | 8.1 (6.9–14.9) | 130 (85) | 10 (4.9–17.4) | .231 |
| White cell count, ×103/µL | 1 (17) | 7.6 (3.5–21.6) | 25 (16.3) | 6.8 (1.0–43.2) | .783 |
| Platelet count, ×103/µL | 4 (67) | 185 (89.0–305) | 29 (19) | 280 (23.0–789) | .050 |
| Albumin, g/L | 5 (83) | 24.0 (16.0–39.0) | 118 (77) | 28.0 (12.0–43.0) | .489 |
| Sodium, mEq/L | 5 (83) | 132 (125–138) | 119 (78) | 131 (113–150) | .692 |
P values are by Fisher exact test or Wilcoxon rank-sum test, as appropriate.
Abbreviations: CRP, C-reactive protein; IL-6, interleukin 6; KICS, Kaposi’s sarcoma–associated herpesvirus inflammatory cytokine syndrome; KSHV, Kaposi’s sarcoma–associated herpesvirus; OD, optical density; ORF, open reading frame; VL, viral load.
a“Abnormal” refers to elevated KSHV-VL, >100 copies/106 cells; positive K8.1 and ORF73, OD values >1 (normalized cutoff); elevated IL-6, >1.8 pg/mL; elevated CRP, >10 mg/L; low hemoglobin, <12 g/dL (female) or <13 g/dL (male); low white cell count <3.9 ×103/µL; low platelet count, <186 ×103/µL; low albumin, <35 g/L; and low sodium, <135 mEq/L.
Selected Laboratory Abnormalities in Patients With Kaposi’s Sarcoma–Associated Herpesvirus Inflammatory Cytokine Syndrome (n = 6) and All Other Group 4 Patients (n = 153)
| Characteristic . | Possible KICS Subjects (n = 6) . | Remainder of Patients Without Microbiologically Proven Coinfection (n = 153) . | P Value . | ||
|---|---|---|---|---|---|
| . | Abnormala, No. (%) . | Median (Range) . | Abnormala, No. (%) . | Median (Range) . | . |
| KSHV-VL, copies/106 cells | 6 (100) | 699.6 (160.7–2 165 641) | 2 (1) | 1.00 (1.00–104 664.39) | < .0001 |
| K8.1 OD | 6 (100) | 2.1 (1.3–2.3) | 46 (30) | 0.48 (0.10–2.57) | .001 |
| ORF73 OD | 4 (67) | 3.3 (0.32–7.4) | 33 (22) | 0.24 (0.03–8.14) | .003 |
| IL-6, pg/mL | 5 (83) | 11.5 (1.6–3 307.4) | 97 (63) | 12.5 (1.6–1 045.4) | .978 |
| CRP, mg/L | 6 (100) | 71.4 (11.1–304) | 131 (85) | 94.0 (0.38–564.9) | .767 |
| Hemoglobin, g/dL | 5 (83) | 8.1 (6.9–14.9) | 130 (85) | 10 (4.9–17.4) | .231 |
| White cell count, ×103/µL | 1 (17) | 7.6 (3.5–21.6) | 25 (16.3) | 6.8 (1.0–43.2) | .783 |
| Platelet count, ×103/µL | 4 (67) | 185 (89.0–305) | 29 (19) | 280 (23.0–789) | .050 |
| Albumin, g/L | 5 (83) | 24.0 (16.0–39.0) | 118 (77) | 28.0 (12.0–43.0) | .489 |
| Sodium, mEq/L | 5 (83) | 132 (125–138) | 119 (78) | 131 (113–150) | .692 |
| Characteristic . | Possible KICS Subjects (n = 6) . | Remainder of Patients Without Microbiologically Proven Coinfection (n = 153) . | P Value . | ||
|---|---|---|---|---|---|
| . | Abnormala, No. (%) . | Median (Range) . | Abnormala, No. (%) . | Median (Range) . | . |
| KSHV-VL, copies/106 cells | 6 (100) | 699.6 (160.7–2 165 641) | 2 (1) | 1.00 (1.00–104 664.39) | < .0001 |
| K8.1 OD | 6 (100) | 2.1 (1.3–2.3) | 46 (30) | 0.48 (0.10–2.57) | .001 |
| ORF73 OD | 4 (67) | 3.3 (0.32–7.4) | 33 (22) | 0.24 (0.03–8.14) | .003 |
| IL-6, pg/mL | 5 (83) | 11.5 (1.6–3 307.4) | 97 (63) | 12.5 (1.6–1 045.4) | .978 |
| CRP, mg/L | 6 (100) | 71.4 (11.1–304) | 131 (85) | 94.0 (0.38–564.9) | .767 |
| Hemoglobin, g/dL | 5 (83) | 8.1 (6.9–14.9) | 130 (85) | 10 (4.9–17.4) | .231 |
| White cell count, ×103/µL | 1 (17) | 7.6 (3.5–21.6) | 25 (16.3) | 6.8 (1.0–43.2) | .783 |
| Platelet count, ×103/µL | 4 (67) | 185 (89.0–305) | 29 (19) | 280 (23.0–789) | .050 |
| Albumin, g/L | 5 (83) | 24.0 (16.0–39.0) | 118 (77) | 28.0 (12.0–43.0) | .489 |
| Sodium, mEq/L | 5 (83) | 132 (125–138) | 119 (78) | 131 (113–150) | .692 |
P values are by Fisher exact test or Wilcoxon rank-sum test, as appropriate.
Abbreviations: CRP, C-reactive protein; IL-6, interleukin 6; KICS, Kaposi’s sarcoma–associated herpesvirus inflammatory cytokine syndrome; KSHV, Kaposi’s sarcoma–associated herpesvirus; OD, optical density; ORF, open reading frame; VL, viral load.
a“Abnormal” refers to elevated KSHV-VL, >100 copies/106 cells; positive K8.1 and ORF73, OD values >1 (normalized cutoff); elevated IL-6, >1.8 pg/mL; elevated CRP, >10 mg/L; low hemoglobin, <12 g/dL (female) or <13 g/dL (male); low white cell count <3.9 ×103/µL; low platelet count, <186 ×103/µL; low albumin, <35 g/L; and low sodium, <135 mEq/L.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
